CN111629754B - 不引起显著红血细胞凝集的抗cd47抗体 - Google Patents

不引起显著红血细胞凝集的抗cd47抗体 Download PDF

Info

Publication number
CN111629754B
CN111629754B CN201980009335.0A CN201980009335A CN111629754B CN 111629754 B CN111629754 B CN 111629754B CN 201980009335 A CN201980009335 A CN 201980009335A CN 111629754 B CN111629754 B CN 111629754B
Authority
CN
China
Prior art keywords
antibody
antibodies
seq
amino acid
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980009335.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111629754A (zh
Inventor
赵涛
张辉辉
杨帅
张赟
周传初
武术
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Publication of CN111629754A publication Critical patent/CN111629754A/zh
Application granted granted Critical
Publication of CN111629754B publication Critical patent/CN111629754B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980009335.0A 2018-01-24 2019-01-24 不引起显著红血细胞凝集的抗cd47抗体 Active CN111629754B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018074055 2018-01-24
CNPCT/CN2018/074055 2018-01-24
PCT/CN2019/072929 WO2019144895A1 (en) 2018-01-24 2019-01-24 Anti-cd47 antibodies that do not cause significant red blood cell agglutination

Publications (2)

Publication Number Publication Date
CN111629754A CN111629754A (zh) 2020-09-04
CN111629754B true CN111629754B (zh) 2023-10-20

Family

ID=67395823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980009335.0A Active CN111629754B (zh) 2018-01-24 2019-01-24 不引起显著红血细胞凝集的抗cd47抗体

Country Status (11)

Country Link
US (1) US20210070855A1 (cg-RX-API-DMAC7.html)
EP (1) EP3743108A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021511064A (cg-RX-API-DMAC7.html)
KR (1) KR20200116109A (cg-RX-API-DMAC7.html)
CN (1) CN111629754B (cg-RX-API-DMAC7.html)
AU (1) AU2019212674A1 (cg-RX-API-DMAC7.html)
CA (1) CA3089512A1 (cg-RX-API-DMAC7.html)
IL (1) IL276188A (cg-RX-API-DMAC7.html)
SG (1) SG11202006877PA (cg-RX-API-DMAC7.html)
TW (1) TW201932493A (cg-RX-API-DMAC7.html)
WO (1) WO2019144895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007646B (zh) * 2019-06-25 2024-05-10 南京金斯瑞生物科技有限公司 抗cd47/抗tigit双特异抗体及其制备方法和应用
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
CN114096564A (zh) * 2019-07-16 2022-02-25 南京金斯瑞生物科技有限公司 抗cd47/抗ctla-4双特异抗体及其制备方法和应用
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4039711A4 (en) * 2019-07-23 2023-11-15 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof
TW202108631A (zh) * 2019-08-21 2021-03-01 大陸商和鉑醫藥(上海)有限責任公司 一種抗cd47抗原結合蛋白及其應用
JP7808546B2 (ja) 2019-09-03 2026-01-29 中山康方生物医▲藥▼有限公司 抗cd47モノクローナル抗体及びその使用
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN112679611B (zh) * 2021-01-18 2022-06-10 倍而达药业(苏州)有限公司 人源化cd47抗体或其抗原结合片段及应用
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
TWI869582B (zh) * 2020-04-10 2025-01-11 大陸商和記黃埔醫藥(上海)有限公司 抗cd47抗體及其用途
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022010806A1 (en) * 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
CN120040592A (zh) * 2020-07-31 2025-05-27 百奥泰生物制药股份有限公司 Cd47抗体及其应用
CA3187837A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Cd47 binding agents and uses thereof
KR20230079393A (ko) * 2020-09-28 2023-06-07 상하이 헨리우스 바이오테크, 인크. 항 cd47 항체 및 사용 방법
KR102757518B1 (ko) * 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
WO2022140659A2 (en) * 2020-12-23 2022-06-30 D-10 Therapeutics, Inc. Anti-cd47 antibodies and uses thereof
US20250277031A1 (en) * 2021-01-08 2025-09-04 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to cd47 and antigen-binding fragment thereof
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
KR102757524B1 (ko) * 2021-06-30 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
US20240336681A1 (en) * 2021-07-30 2024-10-10 Ludwig-Maximilians-Universität München Anti-cd47 antibodies and use thereof
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117257935A (zh) * 2022-06-21 2023-12-22 广东菲鹏制药股份有限公司 一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
CN115932271A (zh) * 2022-09-02 2023-04-07 东曜药业有限公司 一种cd47抗体的试剂组合物及其应用
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN119968212A (zh) * 2022-10-14 2025-05-09 南京传奇生物科技有限公司 靶向cd47的抗体及其用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120584133A (zh) * 2022-12-29 2025-09-02 上海复宏汉霖生物技术股份有限公司 抗cd47抗体及使用方法
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133083A (zh) * 2003-11-11 2008-02-27 中外制药株式会社 人源化的抗cd47抗体
CN104271757A (zh) * 2012-02-06 2015-01-07 印希彼有限责任公司 Cd47抗体及其使用方法
CN106084052A (zh) * 2016-06-17 2016-11-09 长春金赛药业有限责任公司 抗cd47单克隆抗体及其应用
CN107530421A (zh) * 2014-12-30 2018-01-02 细胞基因公司 抗cd47抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
TW201819413A (zh) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Cd47抗體、其抗原結合片段及其醫藥用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133083A (zh) * 2003-11-11 2008-02-27 中外制药株式会社 人源化的抗cd47抗体
CN104271757A (zh) * 2012-02-06 2015-01-07 印希彼有限责任公司 Cd47抗体及其使用方法
CN107530421A (zh) * 2014-12-30 2018-01-02 细胞基因公司 抗cd47抗体及其用途
CN106084052A (zh) * 2016-06-17 2016-11-09 长春金赛药业有限责任公司 抗cd47单克隆抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?;Xi Wen Zhao等;BLOOD;第119卷(第18期);4333-4334 *

Also Published As

Publication number Publication date
IL276188A (en) 2020-09-30
SG11202006877PA (en) 2020-08-28
CA3089512A1 (en) 2019-08-01
EP3743108A4 (en) 2022-01-26
AU2019212674A1 (en) 2020-09-03
JP2021511064A (ja) 2021-05-06
US20210070855A1 (en) 2021-03-11
TW201932493A (zh) 2019-08-16
CN111629754A (zh) 2020-09-04
EP3743108A1 (en) 2020-12-02
WO2019144895A1 (en) 2019-08-01
KR20200116109A (ko) 2020-10-08

Similar Documents

Publication Publication Date Title
CN111629754A (zh) 不引起显著红血细胞凝集的抗cd47抗体
JP6726238B2 (ja) 血小板非減少性かつ赤血球非減少性cd47抗体及びその使用方法
US20210317205A1 (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US20210371522A1 (en) Cd47 antibodies and methods of use thereof
US10689442B2 (en) Antibodies against Frizzled receptor
US20140140989A1 (en) Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
HK40088423A (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
HK40018837A (en) Cd47 antibodies and methods of use thereof
HK1205195B (en) Cd47 antibodies and methods of use thereof
HK1218863B (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant